Bavarian Nordic A/S
XMUN:BV3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bavarian Nordic A/S
XMUN:BV3
|
DK |
|
UL Solutions Inc
F:72R
|
US |
|
M
|
Monument Mining Ltd
DUS:D7Q1
|
CA |
|
Palatin Technologies Inc
OTC:PTNT
|
US |
|
D
|
DB Finance No.10 Special Purpose Acquisition Co Ltd
KOSDAQ:404950
|
KR |
|
K
|
Kyivstar Group Ltd
NASDAQ:KYIV
|
AE |
Bavarian Nordic A/S
Bavarian Nordic is a vaccine company that develops, makes, and sells vaccines for infectious diseases. Its best-known products are vaccines for smallpox and mpox, rabies, and tick-borne encephalitis, along with a few other travel and specialty vaccines. It also works on vaccine candidates for other diseases and immune-related medicines, but its core business is finished vaccines rather than general drug development. Its main customers are governments, public health agencies, military buyers, and travel medicine providers, plus some hospitals and clinics that use its vaccines. Bavarian Nordic makes money by selling vaccine doses and by signing supply contracts with governments and other institutions that want reliable access to stockpiled or emergency-use vaccines. It can also earn income from manufacturing partnerships and development work tied to its vaccine platforms. What makes the business model different is that it sits at the intersection of public health and biotech. Many of its biggest orders come from preparedness needs, not ordinary consumer demand, so sales can be driven by national stockpiles, outbreak response, and long-term supply agreements. That gives the company a role as a specialist supplier of vaccines that governments and health systems need to keep on hand even when a disease is not spreading widely.
Bavarian Nordic is a vaccine company that develops, makes, and sells vaccines for infectious diseases. Its best-known products are vaccines for smallpox and mpox, rabies, and tick-borne encephalitis, along with a few other travel and specialty vaccines. It also works on vaccine candidates for other diseases and immune-related medicines, but its core business is finished vaccines rather than general drug development.
Its main customers are governments, public health agencies, military buyers, and travel medicine providers, plus some hospitals and clinics that use its vaccines. Bavarian Nordic makes money by selling vaccine doses and by signing supply contracts with governments and other institutions that want reliable access to stockpiled or emergency-use vaccines. It can also earn income from manufacturing partnerships and development work tied to its vaccine platforms.
What makes the business model different is that it sits at the intersection of public health and biotech. Many of its biggest orders come from preparedness needs, not ordinary consumer demand, so sales can be driven by national stockpiles, outbreak response, and long-term supply agreements. That gives the company a role as a specialist supplier of vaccines that governments and health systems need to keep on hand even when a disease is not spreading widely.
Strong start: Bavarian Nordic said Q1 was a solid start to 2026, with revenues just over DKK 1 billion and a 16% EBITDA margin.
Guidance raised: The company lifted full-year 2026 guidance after a new U.S. government order, now expecting revenue of DKK 5.5 billion to DKK 5.7 billion and an EBITDA margin of approximately 28%.
Travel Health growth: Travel Health grew 14% excluding discontinued partner revenue, driven by rabies, Vimkunya and TBE, with rabies showing especially strong demand in the U.S. and Germany.
Vimkunya headwinds: U.S. demand for the chikungunya vaccine is being slowed by delayed CDC publication and wholesaler stocking behavior, but management still stood by its DKK 250 million revenue target for the year.
Public Preparedness boost: A new BARDA order helped push secured Public Preparedness contracts to DKK 2 billion and supported expectations for another DKK 300 million to DKK 500 million in additional orders this year.
Cash and capital returns: Cash ended Q1 at about DKK 2.3 billion before the buyback, and management said more cash increases the likelihood of additional share buybacks if no attractive M&A target is found.
